TRLV
Trulieve Cannabis Corp.
TRLV lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
TRLV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Strong |
TRLV's cash flow and balance sheet are currently healthy, but its revenue and profitability are under pressure.
TRLV PE Valuation
TRLV has no meaningful PE right now: it lost money over the past year.
TRLV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TRLV's earnings to grow and its profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
TRLV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.37 | — |
| Q3 2026 | -$2.30 | -$1.66 |
| Q2 2026 | -$2.44 | -$1.62 |
| Q1 2026 | -$0.41 | +$0.38 |
| Q4 2025 | -$0.58 | +$0.21 |
| Q3 2023 | -$2.62 | -$1.35 |
| Q2 2023 | -$2.91 | -$2.19 |
| Q1 2023 | -$1.23 | -$0.94 |
| Q4 2022 | -$1.06 | -983% |
TRLV is still losing money, but less than at its worst: $2.30 per share over the past year, against $2.91 at its worst in mid-2023.
TRLV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $230.2M | -20% |
| Q2 2026 | $271M | -10% |
| Q1 2026 | $286.8M | -3.7% |
| Q4 2025 | $293.1M | -2.7% |
| Q3 2025 | $288.2M | +1.4% |
| Q2 2025 | $302.1M | -0.4% |
| Q1 2025 | $297.8M | 0% |
| Q4 2024 | $301.1M | +4.9% |
TRLV's revenue has slid since its 2022 peak: $230M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +3.8 points |
| Q2 2026 | -137% | -154 points |
| Q1 2026 | 12% | +1.3 points |
| Q4 2025 | 5.2% | +4.8 points |
| Q3 2025 | 15% | +14 points |
| Q2 2025 | 17% | +1 points |
| Q1 2025 | 11% | -4.3 points |
| Q4 2024 | 0.4% | -9.7 points |
TRLV's operating margin was 18% last quarter, up 3.8 points from the same quarter a year ago.
TRLV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $45.4M | -30% |
| Q2 2026 | $32.1M | -57% |
| Q1 2026 | $42.2M | +25% |
| Q4 2025 | $55.8M | +$67.6M |
| Q3 2025 | $64.4M | +$71M |
| Q2 2025 | $74.5M | +66% |
| Q1 2025 | $33.9M | -73% |
| Q4 2024 | -$11.8M | -110% |
TRLV still generates free cash flow, though less than at its 2024 peak: $176M over the past year.
TRLV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +7.9M shares |
| 1 year | +4.9% | +9.3M shares |
| 3 years | +6.2% | +11.7M shares |
| 5 years | +47% | +63.7M shares |
TRLV has 201M diluted shares, up 4.9% from a year ago.
TRLV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | 0.5x | Very low |
| Q2 2024 | 0.0x | Very low |
TRLV has more cash than debt.
TRLV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.1 | Neutral |
| Stochastic | 59.2 | Neutral |
TRLV's weekly RSI is 56 (neutral) and its Stochastic is 59 (neutral).
TRLV PE vs Healthcare Sector
TRLV has no meaningful PE right now: it lost money over the past year.
TRLV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 2.5% above |
| 20 week MA | $10.4 | 7.7% above |
| 50 week MA | $8.85 | 26% above |
| 100 week MA | $7.06 | 58% above |
| 200 week MA | $7.29 | 53% above |
TRLV has climbed back above all five of its weekly moving averages, and it's now 53% above its 200-week average.
TRLV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $31.9 | +195% |
| 2021 | $31.9 | $26.8 | -16% |
| 2022 | $26.8 | $7.58 | -72% |
| 2023 | $7.58 | $5.21 | -31% |
| 2024 | $5.21 | $4.78 | -8.3% |
| 2025 | $4.78 | $7.89 | +65% |
| 2026 YTD | $7.89 | $11.2 | +41% |
TRLV's yearly returns have swung widely, from +195% in 2020 to −72% in 2022. It's up 41% so far in 2026.